The E2F4 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population designed to disrupt the E2F4 gene in the HAP1 near-haploid human cell line. This loss-of-function model enables comprehensive investigation of E2F4-mediated transcriptional control in a heterogeneous polyclonal pool, circumventing the need for clonal isolation and facilitating its application in pooled functional genomics and high-throughput screens.
HAP1 is a near-haploid chronic myeloid leukemia derivative of KBM-7, retaining a stable karyotype with a single disomic region on chromosome 15. This genetic simplicity ensures that CRISPR-mediated disruption of a single allele commonly yields a penetrant phenotype, making HAP1 an ideal host for knockout screening, signaling pathway dissection, and drug-target studies in a leukemic background.
E2F4 functions as a potent transcriptional repressor that restrains cell cycle entry and promotes differentiation. It assembles repressive complexes with the pocket proteins RBL2 (p130) and RBL1 (p107), which further recruit co-repressors including HDAC1, SIN3A, and SMARCA4 to silence E2F-responsive genes such as CCNE1, CDC25A, MYC, BIRC5, TK1, and PCNA. Mitogen-stimulated Cyclin D?CCDK4/6 activity phosphorylates these pocket proteins, dissociating the repressor complex and permitting activator E2F-driven transcription. Upstream, TGF-beta signals through SMAD2/3 to modulate E2F4 activity, linking cytostatic signals to the cell cycle machinery.
Within the HAP1 context, E2F4 inactivation provides a robust platform to dissect its tumor-suppressive roles and its contribution to the interplay among TGF-beta, Wnt, and Hippo pathways. The polyclonal format reduces the risk of clonal artifact, making this population particularly suitable for studying long-term proliferation dynamics, drug resistance evolution, and genotype-phenotype relationships in CML and other cancers where E2F4 is implicated.
This knockout product supports a wide array of experimental readouts, including Western blotting and RT-qPCR for target validation, flow cytometry for cell cycle analysis, and proliferation assays for evaluating therapeutic responses. It is an essential resource for TGF-beta pathway analysis, haploid genetic screens, drug target validation, and cancer therapeutic research. For further information, please contact Ascent Research.
